Hemiplegic migraine (HM) is a rare, genetically heterogenous migraine subtype with aura presenting as recurrent transient attacks of hemicrania and hemiparesis. There are no established evidence-based guidelines for the emergency management of HM, and acute therapy therefore remains empiric.

We report for the first time a successful treatment of a prolonged Na+-K+-ATPase subunit gene ATP1A2 -linked HM attack in a pediatric case with the calcium antagonist nimodipine. Nimodipine treatment is currently established only for management of HM involving calcium channels. Our results suggest that nimodipine can be an effective emergency treatment option for HM devoid of calcium channel pathologies, arguing for suggested effects of nimodipine such as the inhibition of cerebral vasoconstriction.

偏瘫偏头痛 (HM) 是一种罕见的遗传异质性偏头痛亚型，其先兆表现为反复发作的偏头痛和偏瘫。对于 HM 的紧急处理没有既定的循证指南，因此急性治疗仍然是经验性的。

我们首次报告了钙拮抗剂尼莫地平对儿科病例中延长的 Na+-K+-ATPase 亚基基因 ATP1A2 相关 HM 攻击的成功治疗。尼莫地平治疗目前仅用于管理涉及钙通道的 HM。我们的研究结果表明，尼莫地平可以成为无钙通道病变的 HM 的有效紧急治疗选择，支持尼莫地平的建议作用，例如抑制脑血管收缩。